Galera Therapeutics Inc expected to post a loss of 52 cents a share - Earnings Preview

Galera Therapeutics

04/11/2022 19:32

* Galera Therapeutics Inc  GRTX.OQ   GRTX.O  is expected
to show
no change in quarterly revenue when it reports  results on
November 8 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Galera Therapeutics
Inc
is for a loss of 52 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Galera
Therapeutics Inc is $12.5​, above​ its last closing price
of $1.41. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.52       -0.53      -0.54     Missed  -2.4
 Mar. 31 2022  -0.57       -0.57      -0.58     Missed  -1.5
 Dec. 31 2021  -0.74       -0.75      -0.64     Beat    14.7​
 Sep. 30 2021  -0.78       -0.77      -0.86     Missed  -12.4
 ​​Jun.        -0.81       -0.83      -0.88     Missed  -6.2
 30 2021                                                
 Mar. 31 2021  -0.84       -0.83      -0.75     Beat    9.7​
 Dec. 31 2020  -0.68       -0.71      -0.80     Missed  -13
 Sep. 30 2020  -0.77       -0.77      -0.69     Beat    10.5
 This summary was machine generated November 4 at 19:32 GMT.  All
figures in US dollars  unless otherwise stated